Company Overview
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +85.09% |
| 6 Months: | +54.46% |
| 3 Months: | +25.91% |
| 1 Month: | +12.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LBRX LB Pharmaceuticals Inc R2K | 32.02 | -23.54 | $918.23M | 0.00% | - | -19.56% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Net Income | -16.22M | -27.63M | -14.18M | -5.31M | -4.87M | -3.56M | -19.05M |
| Diluted EPS | - | - | -39.49 | -14.79 | - | -0.61 | -0.67 |
| R&D Expense | - | - | 10.66M | 3.42M | - | 2.42M | 14.64M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Net Income | -63.10M | -25.20M |
| Diluted EPS | -176.15 | -3.13 |
| R&D Expense | 51.17M | 16.74M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 33.53M | 312.93M |
| Total Equity | -34.47M | -94.55M | 301.31M |
| Cash & Equivalents | - | 22.98M | 250.17M |
| Total Liabilities | - | 13.83M | 11.62M |
| Current Liabilities | - | 8.11M | 7.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -53.05M | -35.21M |
| Investing Cash Flow | 23.23M | -39.89M |
| Financing Cash Flow | 38.31M | 302.56M |
| Capital Expenditure | -769.00K | -52.00K |
| Free Cash Flow | -53.82M | -35.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 66.7% | -8.4% |
| ROCE % | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, Lp | 11.69% | 3.35M | $112.35M |
| 2 | Blackrock Inc. | 8.62% | 2.47M | $82.80M |
| 3 | RA Capital Management, L.P. | 7.70% | 2.21M | $74.01M |
| 4 | TCG Crossover Management, LLC | 6.41% | 1.84M | $61.64M |
| 5 | Commodore Capital Lp | 5.23% | 1.50M | $50.26M |
| 6 | Caligan Partners, LP | 5.01% | 1.44M | $48.19M |
| 7 | JPMORGAN CHASE & CO | 4.98% | 1.43M | $47.84M |
| 8 | Spruce Street Capital LP | 4.80% | 1.38M | $46.12M |
| 9 | Trails Edge Capital Partners, LP | 4.60% | 1.32M | $44.21M |
| 10 | Nantahala Capital Management, LLC | 3.67% | 1.05M | $35.28M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LBRX
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQRjR2VlJVcGZ6TGdQdnd5U2lHTWNZRG01cEVHdm1JMDNnWWFQVVZQNFlqRC1yLVI3RER2MW1uQjdSVGhRM0tKd3RXVjA0Q3RERnhLVGxKRm1JbzZ0alF4WllLNHRBZjB1c1EyOGVYNmRIYXNVdXdYY0FWbnpFWFU5Vm5PdGhiUFZkOVZERW…
LB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operations - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOT09aUTJQQjhUcm5TYlI2ajd0LUppekJGTk04UlVRVXNUVFpXT1RMV3VPY2toQmU2OXhQUHZSY2s2RUVPcTl1T3RFY0Z1Qml2dHRadGtfVm5fY0tRYk55VXpBUGc3OW9BZHFKWWhfTHF0NkhzdDc3RzZpc0pnNndrSVdBRUJfTWFkUVFiQU…
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQVTNvMlBNN3hqRC0wOVZKalVDR3VSbnFqZmVoVHd2bjBRcDh6QTBFbkdTZHFiNE9UVkEtU1c3TGU1N1VvX1JqTHhjWjVYcEQ5bk1hR0Fta1RJTVlfQW13eW5jTnliQnFVWWJuRThpSzRuWkJsVldQSXd5SVgwUWwyWC1ZZDEzaVdLdW9DSF…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9KQzVta3Z5bDlnQzVFUllrd3FONE9Vc09pbVhuVVY4X0dSQzkzXzBrTEd0Z2lnRk1NSENyNmRFanItZ2FfV1prZy1KVDVXQTRq?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Total assets of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQWTZmR0c2SFRWbzlLWVFUanVPZm9XbF9jNTVRWURYdHRxejJLUlRWZG1LNGlFSlJUMXhaZVpMUGZITEctbW04SHVuQmRFajUxX0k1akpSMHh3dmc1MXZDQjdjMDdrdHBVcEdBMTVXY3NpQnBUems2ejY0aUtyNDdaWlFQS21UZ0VXQWRzOF…
LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOUmZRcDA2SUNSdTFrMUFQbGtfdmFnSVYzdEMtOC1DbWhqZ292elVvMnBmRU92ZFlBd01ZQzhReEM3Snp3NEhKZzJDZDNtaUJHRnJWZ1RCeTlTWmU2SGpYMzlNY01QblhIdDBmSExpcU5OdXNhQTdhNTRHV2RTWEs3ZXV4a3hjQkxZWU9iZl…
LBRX — Frequently Asked Questions
What is the current share price of LB Pharmaceuticals Inc (LBRX)?
As of 2026-07-14 21:23 PDT, LB Pharmaceuticals Inc (LBRX) trades at $32.02 on NasdaqGM. Its 52-week range is $14.61 to $34.29.
What is the market capitalisation of LBRX?
LB Pharmaceuticals Inc (LBRX) has a market capitalisation of $918.23M on NasdaqGM.
What is the P/E ratio of LBRX?
LBRX trades at a trailing price-to-earnings (P/E) ratio of -23.54. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.15.
What is the return on equity (ROE) of LBRX?
LBRX has a return on equity (ROE) of -19.56%.
Is LBRX a good stock to buy?
This page provides a data-driven analysis of LB Pharmaceuticals Inc (LBRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.